An interventional study of Internet-Based Intervention and Internet-Based Intervention in Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm and Melanoma, sponsored by University of Michigan Rogel Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by University of Michigan Rogel Cancer Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 167 studies in Testicular Neoplasms with a site in United States — 21 open to participants now, 26 under way, 1 of them phase 3. Testicular Neoplasms · United States.
Among the 167 studies in Testicular Neoplasms with a site in United States, this one is the 19th largest by planned enrollment of the 111 interventional ones that give a count, is one of 6 that started in 2026, is one of 25 with no phase, reaches primary completion later than 10 of the 25 other live ones, and was the 167th registered.
295 studies on the registry are indexed under Testicular Neoplasms; 51 are open to participants now.
Browse Testicular Neoplasms studies →21 of the 167 studies in Testicular Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18+ · Men only
University of Arizona · Sites in United States
Ages 18+
Kaiser Permanente · Sites in United States
Ages 21–45
City of Hope Medical Center · Sites in United States
Ages 18+ · Men only
AstraZeneca · Sites in United States
Ages 18–130
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Testicular Neoplasms studies recruiting now, 26 (60%) set no upper age limit and 11 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 20 Years to 39 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
167 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 52 · Phase 3 16
First in 1990; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 142 is above the median of 50 across 190 interventional studies indexed under Testicular Neoplasms.
Median enrollment 36 across the 111 interventional studies, 167 across the 35 observational. Of the 135 that completed or were terminated, 33 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 167 have an industry lead sponsor. The 10 most frequent:
University of Michigan Rogel Cancer Center is the lead sponsor of 325 studies on the registry; 49 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 31 (67%) have results posted.
University of Michigan Rogel Cancer Center has 1 study filed under Testicular Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Testicular Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06593665Phase 3Indiana UniversityIntrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection. | 2026-12-31 |
| NCT07259304University of Southern CaliforniaSocial Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | 2026-12-31 |
| NCT04435756SWOG Cancer Research NetworkA Study of miRNA 371 in Patients With Germ Cell Tumors | 2027-01-01 |
| NCT06673329Brian Henick, MDBrodalumab in the Treatment of Immune-Related Adverse Events | 2027-05 |
| NCT07406087Kaiser PermanenteNavigation Intervention for Adolescent and Young Adult Cancer Survivors | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 167 studies in Testicular Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot clinical trial is intended to compare the effect of a psychosocial support tool for young adult (YA)cancer survivors - including high-quality information about their cancer combined with evidence-based psychosocial support - to a support tool providing cancer-specific information alone (minus psychosocial modules). This tool, called Thrive Track, will be for YA patients aged 20-39 with thyroid, melanoma, or testicular cancer. Young adult survivors frequently experience persistent worry and distress that can interfere with coping and reduce quality of life. They are also particularly vulnerable to the emotional impact of cancer and may not have adequate support to manage these concerns. The enhanced version of Thrive Track includes personalized emotional support content and strategies designed to help patients better manage worry and distress. Adding these emotional support tools may provide greater benefit than survivorship education alone in strengthening young adult survivors' ability to manage their emotional well-being.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Subjects from certain vulnerable populations will be excluded as appropriate: fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)
PARTICIPANTS RECRUITED FROM THYCA: Subjects from certain vulnerable populations will be excluded as appropriate fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)
Patients receive access to Thrive Track website with general cancer-specific survivorship care information for up to 3 months.
Other: Internet-Based Intervention · Other: Interview · Other: Questionnaire Administration
Patients receive access to Thrive Track website with general cancer-specific survivorship care information in addition to emotional support content for up to 3 months.
Other: Internet-Based Intervention · Other: Interview · Other: Questionnaire Administration
Receive access to Thrive Track website with general cancer-specific survivorship care information
Receive access to Thrive Track website with general cancer-specific survivorship care information in addition to emotional support content
Ancillary studies
Ancillary studies
Cancer related worry
Cancer-related worry will be evaluated using two 8-item validated scales: 1. Cancer Worry Scale (CWS) 2. An adapted cancer worry scale Overall as well as stratified analyses (by recruitment source and cancer type) will be performed. We will compare mean scores on the two scales between intervention and control subjects at 3 months post intervention. Scores on the CWS scale range from 8 (minimum) to 32 (maximum), with lower scores indicating less cancer-related worry and more favorable outcomes. Scores on the adapted cancer worry scale range from 8 (minimum) to 40 (maximum), with lower scores indicating less cancer-related worry and more favorable outcomes.
Time frame: 3 months post-enrollment
Cancer related distress
Cancer-related distress will be measured using the National Comprehensive Cancer Network Distress Thermometer. Scores on the NCCN Distress Thermometer range from 0 (minimum) to 10 (maximum), with lower scores indicating less distress and more favorable outcomes. Overall as well as stratified analyses (by recruitment source and cancer type) will be performed. We will compare mean scores on the distress thermometer between the intervention and control subjects at 3 months post-intervention using two-sample t-tests.
Time frame: 3 months post-enrollment
Knowledge about worry self-management
This outcome will be evaluated using a team-developed 4-item scale. Scores on this scale range from 4 (minimum) to 16 (maximum), with higher scores indicating better knowledge about how to self-manage worry and more favorable outcomes.
Time frame: 3 months post-enrollment
Confidence/self-efficacy in the ability to self-manage worry
This outcome will be evaluated using an 11-item scale from the Breast Cancer Self Efficacy Scale (BCSE), adapted for all cancers. Scores on this scale range from 11 (minimum) to 55 (maximum), with higher scores indicating better self efficacy to manage cancer-related worry and more favorable outcomes.
Time frame: At 3 months post-enrollment
Resilience
This outcome will be evaluated using a 6-item validated scale, adapted from the Communication and Attitudinal Self-Efficacy Scale (CASE) and the Cancer Control and Outlook Scale. Scores on this scale range from 6 (minimum) to 30 (maximum), with higher scores indicating better resilience to deal with cancer and more favorable outcomes.
Time frame: At 3 months post-enrollment
Ease of tool use
This outcome will be evaluated using a series of 7 questions designed to help understand the participants' experience using the Thrive Track website.
Time frame: At 3 months post-enrollment
Plan to share: Yes — As described in our Data Management and Sharing plan (DMS), all the final data generated from this study will be de-identified and uploaded to the Inter-University Consortium for Political and Social Research (ICPSR). Additionally, the primary outcome results of the study will be reported to ClinicalTrials.gov no later than 1 year after the primary completion date of the trial.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: At the end of the study period
Access criteria: Final data generated from this trial can be requested from ICPSR. All researchers requesting the data will need to complete a questionnaire that will include investigator name(s), institution(s), discipline(s), and initial research question(s). We also shall request each applicant to submit to ICPSR the citations of any peer-reviewed presentations and publications. No data-sharing agreement will be required. This data will be accessible for 10 years after it has been uploaded to the ICPSR.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
Of 31 interventional studies with no phase under Testicular Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 72. This study's planned 12 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Jul 2026 → Dec 2026, primary completion Aug 2027 → Dec 2027 and completion Aug 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Michigan Rogel Cancer Center →